Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Inv. presentation Cert. of designation Appointed director
|
Bionik Laboratories Corp. (BNKL)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/30/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
06/16/2023 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data |
05/31/2023 |
SD
| Form SD - Specialized disclosure report: |
05/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
05/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
04/26/2023 |
8-K
| Quarterly results |
02/23/2023 |
8-K
| Entered into an underwriting agreement for the issuance and sale of notes |
02/08/2023 |
8-K
| Quarterly results |
02/08/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
01/20/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
12/20/2022 |
8-K
| Quarterly results |
12/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
12/07/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
11/17/2022 |
8-K
| Quarterly results |
11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/09/2022 |
8-K
| Quarterly results |
11/07/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
11/04/2022 |
8-K/A
| Quarterly results |
10/25/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
10/13/2022 |
4
| Russo Richard Paul Jr (CEO and President) has filed a Form 4 on Bionik Laboratories Corp.
Txns:
| Granted 60,000 options to buy
@ $0.302, valued at
$18.1k
|
|
10/13/2022 |
8-K
| Amended existing or entered into new employment agreement with an officer
Docs:
|
"SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to the Employment Agreement dated as of the Start Date , as amended pursuant to that First Amendment to Employment Agreement dated October 15, 2021 , by and between Bionik Laboratories Corp., a Delaware corporation, and Richard Russo, is made as of the 6th day of October, 2022 , by and between the Company and the Employee . RECITALS WHEREAS, the Company and the Employee are parties to the Agreement; and WHEREAS, the Company and the Employee desire to amend the Agreement as more particularly set forth herein; and WHEREAS, Section 6.6 of the Agreement provides, in part, that no amendment to the Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties thereto. NOW, THEREFORE, in cons...",
"EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date , by and between BIONIK LABORATORIES CORP., a Delaware corporation , and Dan Gonsalves . RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device research, development and production; and WHEREAS, the Company and the Employee have agreed to enter into an employment relationship upon the terms and subject to the conditions hereinafter set forth. NOW THEREFORE, in consideration of the mutual covenants and promises herein contained and other good and valuable consideration, the parties agree as follows: ARTICLE 1- EMPLOYMENT AND DUTIES 1.1 Appointment . Subject to the terms and conditions of this Agreement, the Company hereby agrees to employ the employee, and ...",
"Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer" |
|
09/08/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/07/2022 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
09/01/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
08/31/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/16/2022 |
8-K
| Quarterly results |
08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/10/2022 |
8-K
| Quarterly results |
08/09/2022 |
8-K
| Quarterly results |
07/21/2022 |
8-K
| Quarterly results |
07/06/2022 |
8-K
| Quarterly results |
06/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/21/2022 |
4
| Gaston-Dreyfus Remi (10% Owner) has filed a Form 4 on Bionik Laboratories Corp.
Txns:
| Converted 77,887 shares
@ $9.5, valued at
$739.9k
|
|
|
|
|